Since the discovery that monocytes, cultured with GM-CSF and IL-4, differentiate into dendritic cells (DC) (1), the idea to use ex vivo generated DC to vaccinate cancer patients against tumor antigens has been largely explored (2, 3). The gene discussed is IL4; the disease is neoplasm.